Tricuspid Valve

This channel is dedicated to news and trends in tricuspid valve interventions, surgical and transcatheter, to manage regurgitation and valve stenosis. The tricuspid valve is a rapidly growing area in structural heart interventions. Minimally invasive transcatheter tricuspid valve replacement (TTVR) and repair using transcatheter edge to edge repair (TEER) clips are expected to become a new standard of care in the next couple years, partly because open heart tricuspid surgery has historically has poor outcomes.

Medicare now covers TriClip procedures for patients with symptomatic tricuspid regurgitation
CMS has finalized a new national coverage determination for T-TEER, sometimes known as transcatheter tricuspid valve repair. Abbott's TriClip is the only device approved by the FDA for T-TEER, but other treatment options are under development.
TTVR with Evoque system linked to positive real-world outcomes after 30 days
According to early real-world data, the FDA-approved Evoque TTVR device is associated with positive outcomes when used to treat severe tricuspid regurgitation.
TAVR patients with moderate or greater TR may face increased risks
When TAVR patients present with moderate or greater tricuspid regurgitation, it could impact the care team's treatment strategy of choice.
Late-breaking clinical trials announced for New York Valves 2025
The three-day event is now in its second year. Each day will feature late-breaking clinical trials focused on a different heart valve.
Cardiologist shares positive first-in-human data on TriCares TTVR device
The new Topaz TTVR system was associated with the consistent elimination of tricuspid regurgitation. In addition, none of the first 20 patients treated with the device required a permanent pacemaker as a result of the procedure.

TAVR provides comparable value for low-risk patients with bicuspid and tricuspid AS

Researchers examined data from more than 3,000 TAVR procedures performed with balloon-expandable valves.

Abbott’s TriClip a safe, effective treatment option for severe tricuspid regurgitation

According to the real-world analysis, treatment with TriClip was associated with no major adverse events and a procedural success rate of 100%.

FDA grants breakthrough device designation to Medtronic TTVR system, approves early feasibility study

According to Medtronic, its Intrepid TTVR system helps meet a “large, unmet clinical need.”

TTVR improves outcomes for patients with severe tricuspid regurgitation

Transcatheter edge-to-edge tricuspid valve repair (TTVR) is an effective treatment option for patients with severe tricuspid regurgitation (TR), according to a new study published in JACC: Heart Failure.

Tricuspid Valve

Medicare now covers TriClip procedures for patients with symptomatic tricuspid regurgitation

TTVR with Evoque system linked to positive real-world outcomes after 30 days

TAVR patients with moderate or greater TR may face increased risks

Late-breaking clinical trials announced for New York Valves 2025

Cardiologist shares positive first-in-human data on TriCares TTVR device